公开(公告)号：US10738125B2

公开(公告)日：2020-08-11

申请号：US16352703

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00 ,  A61P35/02 ,  C07K14/55 ,  C12N15/85

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US11802160B2

公开(公告)日：2023-10-31

申请号：US16782440

申请日：2020-02-05

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61P35/02 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C12N15/85

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20210040221A1

公开(公告)日：2021-02-11

申请号：US16979932

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/00

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions N thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US10745485B2

公开(公告)日：2020-08-18

申请号：US16352717

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/55

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20190322752A1

公开(公告)日：2019-10-24

申请号：US16352703

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Blanka Prinz

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US20240309101A1

公开(公告)日：2024-09-19

申请号：US18470875

申请日：2023-09-20

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  Sergio Quezada ,  James Geoghegan ,  Bianka Prinz

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/05 ,  C07K14/55 ,  C12N15/85

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/05 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

公开(公告)号：US11879014B2

公开(公告)日：2024-01-23

申请号：US16494962

申请日：2018-03-03

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Josephine Salimu ,  Kevin Moulder ,  Beatriz Goyenechea Corzo ,  Pascal Merchiers ,  Sergio Quezada ,  Karl Peggs ,  Frederick Arce Vargas ,  Isabelle Solomon

IPC: C07K16/28 ,  A61K39/00 ,  C07K14/55 ,  A61K45/06

CPC classification number: C07K16/2866 ,  C07K14/55 ,  C07K16/2818 ,  A61K39/0011 ,  A61K45/06 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/60 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.

公开(公告)号：US11851494B2

公开(公告)日：2023-12-26

申请号：US16979931

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C07K14/05

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/05 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US11814434B2

公开(公告)日：2023-11-14

申请号：US16979930

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  James Geoghegan ,  Bianka Prinz ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US20210009703A1

公开(公告)日：2021-01-14

申请号：US16979930

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  James Geoghegan ,  Bianka Prinz ,  Sergio Quezada

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.